MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction
The postmenopausal state is associated with an increased risk of metabolic disorder including reduced energy expenditure and weight gain, leading to higher cardiovascular and cancer risks among other diseases. Mitochondrial-derived peptide (MOTS-c) is a 16–amino acid peptide encoded by mitochondrial DNA. Here, we showed that MOTS-c treatment in mice prevented ovariectomy-induced obesity and insulin resistance. After ovariectomy, low levels of estrogens increased fat mass overload and disturbed normal adipose function, forcing the development of insulin resistance. MOTS-c treatment increased brown fat activation and reduced OVX-induced fat accumulation and inflammatory invasion in white adipose tissue, which contributes to the lower level of fatty acid in serum and liver. Moreover, MOTS-c activated AMPK pathway to improve energy dissipation and insulin sensitivity. And a blocker of AMPK pathway was found to attenuate the role of MOTS-c in the regulation of adipocyte lipid metabolism. In conclusion, MOTS-c is a high potential candidate for chronic treatment of menopausal induced metabolic dysfunction.
• MOTS-c prevents ovariectomy (OVX)-induced body weight gain and insulin resistance.
• MOTS-c reduces fat mass and suppresses inflammatory response under OVX condition.
• MOTS-c sustains the activity of the brown adipose under OVX condition.
• MOTS-c mediates AMPK pathway activation to control adipose metabolic homeostasis.
KeywordsMOTS-c Ovariectomy Metabolic disorder Adipose AMPK
This research was supported by the National Natural Science Foundation of China (NSF: 31571215; NSF: 31270843, NSF: 81330045; NSF: 81730053) and the Military Logistics Research Project (AWS14L008; AWS16J022).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 6.(2005) [Better metabolic control with patient-focused insulin administration]. Medizinische Monatsschrift fur Pharmazeuten 28: 366Google Scholar
- 8.Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, DeStavola BL, Rose S, Dowell A, Wilkes HC, Darbyshire JH, Meade TW, group W (2007) Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. Bmj 335:239CrossRefGoogle Scholar
- 18.Ambrosi TH, Scialdone A, Graja A, Gohlke S, Jank AM, Bocian C, Woelk L, Fan H, Logan DW, Schurmann A, Saraiva LR, Schulz TJ (2017) Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration. Cell Stem Cell 20: 771–784 e776. DOI https://doi.org/10.1016/j.stem.2017.02.009
- 20.Tanna N, Patel K, Moore AE, Dulnoan D, Edwards S, Hampson G (2017) The relationship between circulating adiponectin, leptin and vaspin with bone mineral density (BMD), arterial calcification and stiffness: a cross-sectional study in post-menopausal women. J Endocrinol Investig 40:1345–1353CrossRefGoogle Scholar
- 23.Andersen B, Straarup EM, Heppner KM, Takahashi DL, Raffaele V, Dissen GA, Lewandowski K, Bodvarsdottir TB, Raun K, Grove KL, Kievit P (2018) FGF21 decreases body weight without reducing food intake or bone mineral density in high-fat fed obese rhesus macaque monkeys. Int J Obes 42:1151–1160CrossRefGoogle Scholar